Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21

AIDS

Volumn 30, Issue 2, 2016, Pages 171-183

  Elahi, Shokrollah ^a   Weiss, Robert H ^b,c   Merani, Shahzma ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atorvastatin; HIV infection; Mevalonate pathway; p21

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYSTATIN C; HLA DR ANTIGEN; INTERLEUKIN 6; KI 67 ANTIGEN; MEVALONIC ACID; PHYTOHEMAGGLUTININ; PROTEIN BCL 2; PROTEIN P21; SMALL INTERFERING RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFLAMMATORY AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS ISOLATION; VIRUS REPLICATION; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECTS; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; ATORVASTATIN CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HIV-1; HUMANS; UP-REGULATION; VIRUS REPLICATION;

EID: 84952981382     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000917     Document Type: Article

References (72)

1. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006; 38:893-897.
2. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
3. Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis 2015pii: jiv277 (Epub ahead of print).
4. Nasi M, Pinti M, De Biasi S, Gibellini L, Ferraro D, Mussini C, et al. Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett 2014; 162:329-333.
5. Tsoukas C. Immunosenescence and aging in HIV. Curr Opin HIV AIDS 2014; 9:398-404.
6. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61:511-523.
7. Leng SX, Margolick JB. Understanding frailty, aging, and inflammation in HIV infection. Curr HIV/AIDS Rep 2015; 12:25-32.
8. Sigal A, Baltimore D. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. Cell Host Microbe 2012; 12:132-138.
9. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cellto-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-98.
10. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med 2012; 20:101-105.
11. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697-706.
12. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008; 3:356-361.
13. Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, et al. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS 2015[Epub ahead of print].
14. Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4(R) T-cell counts during antiretroviral therapy. AIDS 2010; 24:1991-2000.
15. Srinivasula S, Lempicki RA, Adelsberger JW, Huang CY, Roark J, Lee PI, et al. Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood 2011; 118:262-270.
16. Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS 2010; 5:511-516.
17. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
18. Eckard AR, McComsey GA. The role of statins in the setting of HIV infection. Curr HIV/AIDS Rep 2015; 12:305-312.
19. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2:517-526.
20. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-987.
21. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003; 2:332-338.
22. Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi XH, Ichinose S, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 2008; 10:471-480.
23. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200:541-547.
24. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78:12062-12065.
25. Maziere JC, Landureau JC, Giral P, Auclair M, Fall L, Lachgar A, et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother 1994; 48:63-67.
26. Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health 2015; 20:380-390.
27. Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res 2008; 58:247-256.
28. Follet J, Corcos L, Baffet G, Ezan F, Morel F, Simon B, et al. The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis. Br J Cancer 2012; 106:685-692.
29. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 2008; 68:2375-2383.
30. Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/R LSL-KrasG12D/R mice. Int J Cancer 2012; 131:1951-1962.
31. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539-540.
32. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001; 15:211-218.
33. Elahi S, Niki T, Hirashima M, Horton H. Galectin-9 binding to Tim-3 renders activated human CD4R T cells less susceptible to HIV-1 infection. Blood 2012; 119:4192-4204.
34. Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther 2008; 7:2015-2022.
35. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4RT cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011; 121:1549-1560.
36. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, et al. Protective HIV-specific CD8RT cells evade Treg cell suppression. Nat Med 2011; 17:989-995.
37. Sattentau QJ, Clapham PR, Weiss RA, Beverley PC, Montagnier L, Alhalabi MF, et al. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS 1988; 2:101-105.
38. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94:1925-1930.
39. Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP. Statins disrupt CCR5 and RANTES expression levels in CD4(R) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One 2007; 2:e470.
40. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, et al. The integrin alpha4beta7 forms a complex with cellsurface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009; 106:20877-20882.
41. De Wit S, Delforge M, Necsoi CV, Clumeck N. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS 2011; 25:1332-1333.
42. Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol 2011; 271:455-461.
43. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(R) T cells in melanoma patients. J Clin Invest 2015; 125:2046-2058.
44. Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One 2013; 8:e70442.
45. Guterres FA, Martinez GR, Rocha ME, Winnischofer SM. Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Exp Cell Res 2013; 319:2977-2988.
46. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
47. Hennekens CH. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin Cardiol 2001; 24:II-2-II-5.
48. Rizzo M, Montalto G, Banach M. The effects of statins on blood pressure: current knowledge and future perspectives. Arch Med Sci 2012; 8:1-3.
49. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100:2671-2679.
50. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78-84.
51. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides graftversus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110:4588-4598.
52. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008; 51:246-252.
53. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004; 173:7641-7646.
54. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4RCD25R T cells. Atherosclerosis 2008; 197:829-839.
55. Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005; 174:5630-5635.
56. Xu SZ, Zhong W, Watson NM, Dickerson E, Wake JD, Lindow SW, et al. Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. J Thromb Haemost 2008; 6:692-700.
57. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
58. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128-1131.
59. Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials 2014; 15:1-13.
60. Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396-404.
61. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203:756-764.
62. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209:1156-1164.
63. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595.
64. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
65. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56:1471-1479.
66. Negredo E, Clotet B, Puig J, Perez-Alvarez N, Ruiz L, Romeu J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 2006; 20:619-621.
67. Rodriguez B, Valdez H, Mijch A, Watson K, Lederman MM, McComsey GA, et al. Statins blunt HAART-induced CD4 T-cell gains but have no long-term effect on virologic response to HAART. J Int AssocPhysicians AIDSCare (Chic) 2007; 6:198-202.
68. Rodriguez-Perea AL, Montoya CJ, Olek S, Chougnet CA, Velilla PA. Statins increase the frequency of circulating CD4R FOXP3R regulatory T cells in healthy individuals. J Immunol Res 2015; 2015:762506.
69. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10:48-57.
70. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(R) T cell effector function. Cancer Cell 2014; 26:923-937.
71. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 2014; 40:569-581.
72. Narayan S, Hawley N, Giguere P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors.HIVClin Trials 2003; 4:164-169.